



Medicines & Healthcare products
Regulatory Agency

10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom
[gov.uk/mhra](https://www.gov.uk/mhra)

[REDACTED]

23rd May 2023

FOI 23/301

Dear [REDACTED]

Thank you for your enquiry dated 21st April, where you requested the number of Yellow Card reports submitted by the London Ambulance Service or paramedics from London postcodes for each month in the last available year of data.

As per your request, we have searched for all spontaneous suspected UK Adverse Drug Reaction (ADR) reports between 1st May 2022 and 30th April 2023 using the above search criteria. Between this period, I can confirm that we received 7 Yellow Card reports. With regards to your request for these reports by month and information on further details of category e.g. medicine name, reaction, and outcome, where less than 5 reports are received for a specific category we are unable to provide a detailed breakdown in order to comply with data protection laws and protect patient/reporter confidentiality. As such we are unable to provide any further information on these reports.

Furthermore, please also note that the qualification field is not always filled out accurately by the reporter, for example, a paramedic or someone from the London Ambulance Service may have selected "Other Healthcare Professional" or "Hospital Healthcare Professional". Therefore, the data should not be used as a basis for determining reporting rates.

The MHRA is committed to improving patient safety and strategically runs regular public health campaigns to raise awareness about the importance of reporting to the Yellow Card scheme. You may be interested to view the resources and campaigns tabs on the Yellow Card website [Yellow Card Scheme - MHRA](#).

The Commission on Human Medicines (CHM) are regularly informed of trends and themes in healthcare professional ADR reporting as well as any planned public health campaigns to raise awareness. You may also be interested to know that the MHRA commissions five regional Yellow Card Centres (YCCs) to support the education and promotion of Yellow Card reporting in their region. They are involved in various programmes which improve ADR reporting, including the establishment of nominated hospital pharmacists or pharmacy technicians as

'Yellow Card Champions'. YCCs also work with devolved administrations and local healthcare professional bodies as well as local patient organisations to increase awareness and education about the importance of Yellow Card reporting for patient safety. Contact details for the 5 YCCs can be found [here](#).

If you plan on sharing or publishing the data within this response more widely, please provide us with a copy beforehand so we can ensure correct interpretation.

If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.

If you are unhappy with our decision, you may ask for it to be reviewed. That review will be undertaken by a senior member of the Agency who has not previously been involved in your request. If you wish to pursue that option please write to the Communications Directorate, Medicines and Healthcare products Regulatory Agency, (via this email address). After that, if you remain dissatisfied, you may ask the Information Commissioner at:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF

Copyright notice

The information supplied in response to your request is the copyright of MHRA and/or a third party or parties and has been supplied for your personal use only. You may not sell, resell or otherwise use any information provided without prior agreement from the copyright holder.

The MHRA information supplied in response to your request is subject to Crown copyright. The FOIA only entitles you to access to MHRA information.

For information on the reproduction or re-use of MHRA information, please visit <https://www.gov.uk/government/publications/reproduce-or-re-use-mhra-information/reproduce-or-re-use-mhra-information>

Yours sincerely,

FOI Team

Vigilance and Risk Management of Medicines Division